Table 1 Clinical characteristics of study population
Variables, n (%) or mean ± S.D (range) | Entecavir N = 144 | TAF N = 83 | p value |
|---|---|---|---|
Age (years) | 54.5 ± 10.5 | 55.5 ± 9.8 | 0.473 |
Gender (male: female), n | 44:100 | 34:49 | 0.112 |
Use of rituximab, n (%) | 16 (11.1%) | 6 (7.2%) | 0.341 |
Use of steroid, n (%) | 15 (10.4%) | 4 (4.8%) | 0.142 |
Use of anthracycline, n (%) | 51 (35.4%) | 25 (30.1%) | 0.415 |
Hematologic malignancy, n (%) | 17 (11.8%) | 10 (12%) | 0.957 |
Distant metastasis | 21 (14.6%) | 16 (19.2%) | 0.356 |
Liver metastasis | 7 (4.9%) | 3 (3.6%) | 0.750 |
AST (U/L) | 35.0 ± 55.8 | 28.4 ± 19.5 | 0.298 |
ALT (U/L) | 43.0 ± 96.8 | 31.6 ± 32.3 | 0.299 |
Total bilirubin (mg/dL) | 0.63 ± 0.38 | 0.71 ± 0.46 | 0.153 |
Platelet × 103/μL | 248.4 ± 83.8 | 250.3 ± 102.7 | 0.881 |
FIB-4 | 1.39 ± 0.94 | 1.42 ± 0.91 | 0.822 |
HBV DNA (log10 IU/mL) | 2.85 ± 1.66 | 2.80 ± 1.54 | 0.836 |
Low-viremia group, n (%) | 36 (25%) | 24 (28.9%) | 0.541 |
Moderate-viremia group, n (%) | 61 (42.4%) | 29 (34.9%) | |
High-viremia group, n (%) | 47 (32.6%) | 30 (36.1%) | |
Treatment duration (weeks) | 60.6 ± 25.1 | 55.7 ± 18.6 | 0.116 |
Consolidation duration (weeks) | 30.2 ± 10.8 | 31.1 ± 10.8 | 0.555 |